Latest KFF Health News Stories
With U.S. cases skyrocketing, demand for Gilead’s dark horse antiviral is only growing. Biden appointees propose potential legal tactics to tamp down the price for patients.
Health Issues Carried Weight on the Campaign Trail. What Could Biden Do in His First 100 Days?
KHN has teamed up with PolitiFact to track what becomes of President Joe Biden’s 2020 campaign promises over the next four years. As he moves into the West Wing, what are his chances of making progress on health care?
Aunque controlen el Senado, demócratas necesitarán apoyo republicano en temas clave de salud
Con el control del Senado y la Cámara de Representantes, tendrán el poder de elegir qué propuestas de salud se votarán en el Congreso. Pero no será tan fácil.
Even With Senate Control, Democrats Will Need Buy-In From GOP on Key Health Priorities
With a majority too small to eliminate the filibuster, Democrats will not have enough votes in the Senate to pass many of their plans without Republicans and will also have only a razor-thin majority in the House. This combination could doom many Democratic health care proposals, like offering Americans a government-sponsored public insurance option, and complicate efforts to pass further pandemic relief.
Biden’s First Order of Business May Be to Undo Trump’s Policies, but It Won’t Be Easy
President Donald Trump made substantial changes to the nation’s health care system using executive branch authority. But reversing policies that Democrats oppose would take time and personnel resources, competing with other priorities of the new administration.
Many Health Plans Now Must Cover Full Cost of Expensive HIV Prevention Drugs
Most private insurance will be required to cover drugs, like Truvada, that offer protection against HIV infection, without making plan members share the cost.
Seniors Face Crushing Drug Costs as Congress Stalls on Capping Medicare Out-Of-Pockets
While many private insurers cap what members pay in health costs, Medicare does not. Democrats and Republicans in Congress have proposed annual limits ranging from $2,000 to $3,100. But there’s disagreement about how to pay for that cost cap.
KHN’s ‘What the Health?’: 2020 in Review — It Wasn’t All COVID
The coronavirus pandemic colored just about everything in 2020. But there was other health policy news that you either never heard or might have forgotten about: the Affordable Care Act going before the Supreme Court with its survival on the line; ditto for Medicaid work requirements. And a surprise ending to the “surprise bill” saga. Joanne Kenen of Politico, Anna Edney of Bloomberg News and Sarah Karlin-Smith of Pink Sheet join KHN’s Julie Rovner to discuss these issues and more.
Surprise Federal Drug Rule Directs Insurers to Reveal What They Pay for Prescription Drugs
A provision the Trump administration tucked into its final rule on health plan price transparency requires telling consumers what they will pay out-of-pocket for drugs and showing them what the plan paid.
A $200 Debit Card Won’t Do Much for Seniors’ Drug Costs
President Donald Trump wants to send seniors $200 apiece. Beyond the legal and logistical problems, health care experts point out it does little to help someone with even typical prescription costs.
Florida Fails to Attract Bidders for Canada Drug Importation Program
No private firms bid on the $30 million contract to set up and operate the state’s plan to bring in cheaper drugs. The setback is likely to delay by at least several months Florida’s effort to become the first state to import drugs under new federal regulations.
Progressive Group Highlights Trump, Tillis Weakness on Insulin Price Tags
The progressive Change Now PAC launched a campaign ad, which also circulated on Facebook, criticizing President Donald Trump and Sen. Thom Tillis (R-N.C.) for not “fighting” for people with diabetes who struggle with the high cost of insulin.
Not Pandemic-Proof: Insulin Copay Caps Fall Short, Fueling Underground Exchanges
Although sharing prescription medicines is illegal, many people with diabetes are turning to underground donation networks when they cannot afford their insulin. Caps on insulin copays enacted in Colorado and 11 other states were designed to help. But the gaps between insulin costs and many patients’ financial realities are only widening amid the economic crisis of the COVID pandemic.
Old Drug Turned ‘Cash Cow’ as Company Pumped Price to $40K a Vial, Emails Show
The CEO of Mallinckrodt Pharmaceuticals defended the price hikes of Acthar gel, an orphan drug that treats infantile spasms at a House Oversight Committee hearing on Thursday.
KHN’s ‘What the Health?’: Election Preview: What’s Next for Health?
How will health issues affect voter choices? What will happen if President Donald Trump is reelected or the White House goes to Joe Biden? In this special election preview episode, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
New Laws Keep Pandemic-Weary California at Forefront of Health Policy Innovation
Gov. Gavin Newsom approved many consequential health care bills by his bill-signing deadline Wednesday, including a ban on the sale of menthol and other flavored tobacco products, the creation of a state generic drug label and better coverage for mental health disorders.
Sky-High Drug Prices Driven by Pharma Profits, House Dems Charge
Democrats on the House Oversight Committee released a damning investigation Wednesday of drug company pricing tactics and profits, as two days of hearings with testimony from pharmaceutical industry CEOs begin.
Promises Kept? On Health Care, Trump’s Claims of ‘Monumental Steps’ Don’t Add Up
The president entered office seeking to overturn the Affordable Care Act, revamp Medicaid and drive down prescription drug prices, among other things. He’s hit some stone walls.
KHN’s ‘What the Health?’: ACA in Peril With Ginsburg’s Seat in Play
The death of Supreme Court Justice Ruth Bader Ginsburg is giving new life to the latest constitutional challenge to the Affordable Care Act. It also places anti-abortion activists on the cusp of a court majority large enough to ensure the rollback of the right to abortion and, possibly, some types of birth control. Meanwhile, Health and Human Services Secretary Alex Azar tries to centralize power at the sprawling department plagued by miscommunications and scandals. Anna Edney of Bloomberg News, Kimberly Leonard of Business Insider and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Sarah Jane Tribble about her new podcast, “Where It Hurts,” debuting Sept. 29.
It’s Not Just Insulin: Lawmakers Focus on Price of One Drug, While Others Rise Too
While insulin is the poster child for outrageous prescription costs, patients are paying ever more to treat depression, asthma, HIV, cholesterol and more. And the pandemic has overtaken efforts to force the issue in Congress.
